In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
|Articles|March 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 3
- Volume 15
- Issue 3
Zactima Gets Fast Track Status for Medullary Thyroid Cancer
AstraZeneca, Zactima, ZD6474, medullary thyroid cancer
Advertisement
WILMINGTON, DelawareAstraZeneca's Zactima (ZD6474) has received FDA fast track designation for the treatment of medullary thyroid cancer. Zactima, a once-daily oral agent, targets tumor cells through inhibition of EGFR and REarranged during Transfection (RET) tyrosine kinases, and tumor blood supply through inhibition of VEGFR tyrosine kinase. Zactima, which also has orphan drug status for medullary thyroid cancer, is currently being evaluated in a phase II clinical trial.
Articles in this issue
over 20 years ago
FDA Approves Eraxis to Treat Candidemiaover 20 years ago
NeoGuide's New Colonoscopy System Addresses ‘Looping'over 20 years ago
New Budget Plan Cuts NCI Funding by 0.8% for FY 2007over 20 years ago
Lilly Oncology on Canvas Invites Entriesover 20 years ago
Shorter FEC + Pac Ups DFS in Breast Caover 20 years ago
Xyotax Fast Tracked for Advanced NSCLC in Womenover 20 years ago
FDA Guidances for Early Human Testing of New Drugsover 20 years ago
Darbepoetin During RT Boosts Hb Level, With QOL Benefitover 20 years ago
Breast, Colorectal Cancer Care Quality 'Excellent'over 20 years ago
Dose-Dense Adjuvant Chemo Validated in Breast CancerAdvertisement
Related to this article
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma
5